More News! European Companies Join the Nasdaq Biotech Index

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

  • A horde of European biotechs including Cellectis, Adaptimmune, uniQure, and Galapagos have joined the Nasdaq Biotech Index.
  • Vernalis will collaborate with Daiichi Sankyo on drug discovery research.
  • 4SC took home an undisclosed milestone payment from Immunic.
  • Medherent, a medtech focused on transdermal drug delivery, raked in £3.8M (€4.1M) in a financing round.
  • Bone Therapeutics will collaborate with Czech tissue clinic Cellthera on a bone cell therapy pipeline.
  • Ablynx reported some extra results from its Phase III trial that speak to the cost efficacy of what might become its first product.
  • An autoimmune and inflammatory disease candidate from Immunic cleared two Phase I trials for pharmacokinetics and safety.
  • Cellnovo got a CE mark for its Android- and Bluetooth-enabled insulin pump.

  • Carbios joined the Sustainable Packaging Coalition, whose aim is to “strengthen and advance the business case” for environment-friendly packaging.
  • Sanofi is facing more fallout from one of its products: it’s recalling injectable gel for arthritis, citing microbial contamination.
  • Novo Nordisk has a new multimillion-euro incubator, the BioInnovation Institute, for the development and maturation of the best research projects in Danish life sciences.

Images via FACTORYPIC, Damsea, kungverylucky, Sviluppo, Parkol / shutterstock.com

SaveSave

SaveSave

SaveSaveSaveSave

SaveSave

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.